Idelalisib Shows Promising Activity in Heavily Pretreated iNHL OncLive The majority of patients (89%) had stage III or IV disease and all patients had not responded favorably to rituximab and an alkylating agent or had relapsed within 6 months of treatment. The median patient age was 64 years and the median number of ... |
